Funding Search - Pivot

The University of Vermont, through Sponsored Project Administration (SPA) subscribes to Pivot, a web-based funding search tool. The UVM Cancer Center has collaborated with SPA to create a customized cancer relevant pivot search. Press the button for Cancer Funding Opportunities.

Cancer Funding Opportunities

 

If you would prefer to set up your own pivot search and automated alerts you can learn more about pivot HERE.


Limited Competition Funding

Limited Competitions (where the University may only submit a restricted number of applications) are managed though UVM's InfoReady Portal for Institutional Competitions. Go to https://uvm.infoready4.com/# to see all available competitions and enter “cancer” into the search box to see only cancer-specific opportunities.

You can also contact Edward North for information on applying for Limited Funding Opportunities. 

Peer-Reviewed Funding Sources

Below is a list of fund sources from federal agencies, non-profit foundations and regional and national organizations to support cancer research are provided below for UVM Cancer Center researchers. This of funding is considered NCI approved peer-reviewed funding and can also be found in PDF format at the following link: NCI Peer-Reviewed Fund Sources

  1. Agency for Healthcare Research and Quality (AHRQ)
  2. Alex’s Lemonade Stand Foundation (ALSF)
  3. American Association of Cancer Research (AACR)
  4. American Cancer Society (ACS) (national office only)
  5. American Foundation for AIDS Research (amfAR)
  6. American Institute for Cancer Research (AICR)
  7. California Institute for Regenerative Medicine (CIRM)
  8. Cancer Prevention Research Institute of Texas (CPRIT)
  9. Center for Disease Control and Prevention (CDC)
  10. Central Office of the Veterans Administration (VA) (excluding local/regional & “block” grants)
  11. Environmental Protection Agency (EPA)
  12. The Flight Attendant Medical Research Institute (FAMRI)
  13. Florida Biomedical Research Program (FBRP)
  14. Food and Drug Administration (FDA)
  15. Howard Hughes Medical Institute (HHMI)
  16. Leukemia and Lymphoma Society (LLS)
  17. Melanoma Research Alliance (MRA)
  18. Multiple Myeloma Research Foundation (MMRF)
  19. National Institute for Occupational Safety and Health (NIOSH)
  20. National Science Foundation (NSF)
  21. New York State Department of Health Wadsworth Center/New York State Stem Cell Science Program (NYSTEM)
  22. Patient-Centered Outcomes Research Institute (PCORI)
  23. Prevent Cancer Foundation (PCF)
  24. Prostate Cancer Foundation (PCF)
  25. Susan G. Komen for the Cure
  26. The California Breast Cancer Research Program (CBCRP)
  27. The California Tobacco Related Disease Research Program (TRDRP)
  28. U.S. Army (DOD) special research programs *

 

For Pivot Assistance

Please review the information provided by SPA

Hilda Alajajian, Grant Resources Specialist is available to meet with individuals or groups for assistance in identifying funding

Phone: (802)656-1322

Should you learn of an opportunity not listed here but important to UVM Cancer Center research, please contact Laura Gordon.

UVMCC Facilities & Resources Descriptions

“Boilerplate” descriptions of UVM Cancer Center-affiliated Resources & Facilities are provided at the links below. These are primarily intended for use in grant applications, including the “Facilities & Resources” section of NIH funding applications. Users are strongly urged to personalize the description to the greatest extent possible by adding details such as a history of collaboration resulting in publications and/or funded research awards.
University of Vermont Cancer Center (UVMCC)
Biobank
Cancer Translational Research Laboratory (CTRL)
Clinical Trials Office (CTO)
Microscopy Imaging Center (MIC)
Vermont Integrative Genomics Resource (VIGR)

 

Highlights: New & Updated

New and Updated

AACR-Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Research Fellowship

The AACR-Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Research Fellowship is a joint effort to support and encourage innovative research projects with direct applicability and relevance to ILC and to help establish a successful career path in the field. This fellowship provides a two-year grant of $120,000 to support the salary and benefits of postdoctoral or clinical research fellows working on mentored ILC research projects. A portion of these funds may be designated for non-personnel expenses such as research/laboratory supplies, equipment, publication charges for manuscripts that pertain directly to the funded project, and other research expenses.

https://www.aacr.org/wp-content/uploads/2021/04/2021-AACR-LBCA-Fellowship_LOI-PG.pdf

Deadline: July 6, 2021

American Cancer Society

Grant opportunities and Grantsmanship tips (Workshop)

Wednesday, August 11, 2021, 2-3:30 pm

The American Cancer Society awards research grants and fellowships to promising scientists early in their careers who have unique hypotheses for cancer prevention and study, fostering the next generation of cancer research and creating a strong foundation of preliminary evidence to make scientific advancements. The Society also sponsors grants that support training for health professionals seeking to develop their clinical expertise and/or their ability to conduct independent research.

Workshop objectives:

  • Provide overview of American Cancer Society funded grants and research
  • Provide “Insider Tips” for a successful application process
  • Understand how grants will be evaluated
  • Understand success rates in future funding
  • Understand online resources

Registration required by August 4, 2021 https://forms.office.com/Pages/ResponsePage.aspx?id=jHa7r4LWrUKPfnIC0GwLYZUaUWAhnDVLrhIArezo2OpUQ1M3OVAwUUMzT0NMNlVGQUROVDVMTU5XSS4u&wdLOR=c1609F88F-67A4-419B-96F3-C31FFE64EA15  

Questions? Contact Amy Deavitt at amy.deavitt@cancer.org or Suzi Ford at suzi.ford@cancer.org

Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery.

Deadline: October 5, 2021

https://grants.nih.gov/grants/guide/pa-files/PAR-19-360.html

NCI Transition Career Development Awards (K22)

Facilitates the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.

Deadline: October 12, 2021

NCI Transition Career Development Award (K22 - Independent Clinical Trial Not Allowed) https://grants.nih.gov/grants/guide/pa-files/PAR-21-128.html

NCI Transition Career Development Award (K22 - Independent Clinical Trial Required) https://grants.nih.gov/grants/guide/pa-files/PAR-21-111.html

NCI Transition Career Development Award (K22 Independent Basic Experimental Studies with Humans Required) https://grants.nih.gov/grants/guide/pa-files/PAR-21-318.html

Tobacco Control Policies to Promote Health Equity (R21 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing disparities in tobacco use and secondhand smoke (SHS) exposure in the U.S. Specifically, this FOA aims to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of this FOA is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations. Applicants submitting applications related to health economics are encouraged to consult NOT-OD-16-025 to ensure that the research projects align with NIH mission priorities in health economics research.

Deadline: October 16, 2021

https://grants.nih.gov/grants/guide/pa-files/PAR-20-303.html

Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF)

Innovation Grant

The Innovation Grant is designed to provide critical and significant seed funding for researchers with a novel approach to pediatric oncology scientific investigation. Proposals should have clinical translation in view. This may represent a change in research direction and/or an innovative new idea that moves away from an investigator’s prior research but for which a strong case is made for the potential impact on childhood cancers. The requested budget should be in proportion to the scope of the proposed project and should be at or under $250,000 USD in direct costs over two years. A maximum of $125,000 in total costs may be requested per year.

  • Applicants must have an MD, PhD, or MD/PhD or equivalent and be appointed as faculty (or equivalent) at an academic institution.
  • Applicants must have a track record of publication and funding productivity that demonstrates that the project can be accomplished by the investigators.
  • Applicant institutions may be based in the United States or Canada, and applicants need not be United States citizens. Funds must be granted to nonprofit institutions or organizations.

Anticipated Deadline: November 4, 2021

http://www.alexslemonade.org/grants/guidelines 

Department of Defense Rare Cancers Research Program - Anticipated Funding Opportunities for Fiscal Year 2021 (FY21): Concept Award

Applications submitted to the FY21 RCRP must address one or more of the following Focus Areas:

 

  • Biology and Etiology: Identify disease-defining molecular pathways, cell context, and microenvironment.
  • Research Model: Develop and validate rare tumor-specific models that can support clinical trial readiness.
  • Therapy: Identify novel therapeutic strategies, including drug repurposing.

Investigators at or above the level of postdoctoral fellow

 

  • Supports innovative, high-risk/high-reward research that is in the earliest stages of idea development or an untested theory that addresses an important problem related to rare cancers.  Proof-of-concept is the anticipated outcome.
  • Reviewers will be blinded to the identity of the Principal Investigator, collaborators,and their organization(s).
  • Submission must address at least one of the FY21 Focus Areas of Biology and Etiology,Research Model, and/or Therapy.
  • Preliminary data are not required.
  • Clinical trials are not allowed.
  • Maximum funding of $100,000 for direct costs (plus indirect costs) 
  • Maximum period of performance is 1 year

https://cdmrp.army.mil/pubs/press/2021/21rcrppreann

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. 

Submission deadlines are not available until the program announcements are released.  For email notification when program announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. 

 

Department of Defense Rare Cancers Research Program - Anticipated Funding Opportunities for Fiscal Year 2021 (FY21): Idea Development Award

Applications submitted to the FY21 RCRP must address one or more of the following Focus Areas:

 

  • Biology and Etiology: Identify disease-defining molecular pathways, cell context, and microenvironment.
  • Research Model: Develop and validate rare tumor-specific models that can support clinical trial readiness.
  • Therapy: Identify novel therapeutic strategies, including drug repurposing.

Investigators at or above the level of Assistant Professor

  • Pre-proposal submission is required; application submission is by invitation only.
  • Supports innovative, high-risk/high-reward research with the potential to yield impactful data in the rare cancer field.
  • Preliminary data with disease-specific rationale (including correlatives in existing trials) to support the feasibility of the research hypotheses and research approaches are required. 
  • Submission must address at least one of the FY21 Focus Areas of Biology and Etiology,Research Model, and/or Therapy.
  • Clinical trials are not allowed.
  • Maximum funding of $350,000 for direct costs (plus indirect costs)  
  • Maximum period of performance is 3 years

https://cdmrp.army.mil/pubs/press/2021/21rcrppreann

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. 

Submission deadlines are not available until the program announcements are released.  For email notification when program announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. 

 

Department of Defense Rare Cancers Research Program - Anticipated Funding Opportunities for Fiscal Year 2021 (FY21): Resource and Community Development Award

Applications submitted to the FY21 RCRP must address the Focus Areas below:

 

  • Platform Development: Development of platforms (such as tumor tissue repository with clinical annotation, centralized databanks, patient registry with common data structure, research model and Omics database, longitudinal studies of natural history, and treatment response) for multiple rare cancers, to allow sharing of data, bio-specimens, and resources.

Investigators at or above the level of Assistant Professor

  • Pre-proposal submission is required; application submission is by invitation only.
  • Emphasis on research resources development to facilitate collaboration and information sharing among stakeholders such as researchers, patients, family members, caregivers, clinicians, and other members of the rare cancers community. 
  • Supports platform development or infrastructure that can be applied to multiple rare cancers.
  • Preliminary data are not required but may be included (translational research and clinical studies may be included).
  • Submission must address the Platform Development Focus Area.
  • Clinical trials are not allowed.
  • Maximum funding of $600,000 for direct costs (plus indirect costs) 
  • Maximum period of performance is 3 years

https://cdmrp.army.mil/pubs/press/2021/21rcrppreann

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. 

Submission deadlines are not available until the program announcements are released.  For email notification when program announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.